Back to homepage

Haematology and Oncology

Synchronous GISTs associated with multiple sporadic tumors: a case report

Authors: Danila Comandini, Azzurra Damiani, Alessandro Pastorino

The authors report a case of primary prostate and lung tumors associated with gastric and small bowel GISTs, unrelated to any known hereditary syndrome.

More

Long-term efficacy and safety of fourth-line multikinase inhibitor treatment with lenvatinib in a young papillary thyroid carcinoma patient

Authors: S. Morelli, E. Puxeddu

This article reports on the case of a young papillary thyroid cancer patient, pretreated with three other kinase inhibitors, who achieved a long-term clinical benefit from lenvatinib in the fourth-line setting.

More

Advances in iron chelation therapy: transitioning to a new oral formulation

Authors: Nirmish R Shah

This review provides an overview of the currently available iron chelator formulations, with a focus on a comparison between deferasirox DT for oral suspension and deferasirox FCT. The new formulation may be associated with fewer side effects and has increased bioavailability. In addition, alternative strategies for iron chelation, such as combining two different iron chelators, will be discussed.

More

Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer

Authors: Ivelina Gueorguieva, Ann Cleverly, Durisala Desaiah, Analia Azaro, Joan Seoane, Irene Braña, Elisabet Sicart, Colin Miles, Michael M Lahn, Malcolm I Mitchell, Jordi Rodon

In this relative bioavailability study comparing galunisertib formulations after a single dose, RCD and RCS formulations had similar exposure and safety profile compared with the HSWG formulation.

More

Evaluating cost benefits of combination therapies for advanced melanoma

Authors: Ivar S Jensen, Emily Zacherle, Christopher M Blanchette, Jie Zhang, Wes Yin

The model presented in this study was used to analyze the clinical and economic benefit of using combination therapies in advanced melanoma patients with the BRAF V600 mutation. The analysis suggests dabrafenib + trametinib therapy is associated with less patient time and lower costs relative to nivolumab + ipilimumab to gain similar progression-free survival and overall response rate benefits.

More